Drug intelligence / Profile preview

VS-501

Development stage: Preclinical
Lead developer: VSPharmTech
Modality: Small Molecules

Overview

VS-501 is a preclinical-stage small molecule migrastatic agent being developed by VSPharmTech. It is designed to inhibit the metastatic spread of cancer by targeting the migration and invasion of cancer cells. The compound modulates a specific protein involved in these processes, although the exact molecular target has not been publicly disclosed. Preclinical studies have demonstrated activity in colon cancer models, with potential applications in lung and pancreatic cancers. VSPharmTech holds substance patents for VS-501 in several jurisdictions, including Korea, Australia, and Japan.

Beyond the preview

Go deeper on VS-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-501.

Explore the full profile